Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q3 2022 · 10-Q
Revenue$120.13M$120.13M+7.1% vs Q3 2021 Net Income$15.87M$15.87M−46.3% vs Q3 2021 EPS Diluted$0.30$0.30−49.2% vs Q3 2021 Gross Profit$58,510,000+14.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flowderived$20,375,000+693.1% Free Cash Flowderived$14,752,000N/M Margins · derivedGross margin48.7%+3.1 pt vs Q3 2021
Operating margin19.3%−2.7 pt vs Q3 2021
Net margin13.2%−13.1 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 8, 2022 · 39 d after period end